Free Trial

Richard Law Analyst Performance

Analyst at The Goldman Sachs Group

Richard Law is a stock analyst at The Goldman Sachs Group focused in the medical sector, covering 15 publicly traded companies. Over the past year, Richard Law has issued 25 stock ratings, including buy, hold, and sell recommendations. While full access to Richard Law's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Richard Law's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
34 Last 1 Years
Buy Recommendations
52.94% 18 Buy Ratings
Companies Covered
15 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy52.9%18 ratings
Hold38.2%13 ratings
Sell8.8%3 ratings

Out of 34 total stock ratings issued by Richard Law at The Goldman Sachs Group, the majority (52.9%) have been Buy recommendations, followed by 38.2% Hold and 8.8% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
93.3% of companies on NASDAQ
14 companies
NYSE
6.7% of companies on NYSE
1 company

Richard Law, an analyst at The Goldman Sachs Group, currently covers 15 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
14 companies
93.3%
Manufacturing
1 company
6.7%

Richard Law of The Goldman Sachs Group specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
12 companies
80.0%
MED - DRUGS
2 companies
13.3%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
1 company
6.7%

Richard Law's Ratings History at The Goldman Sachs Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
5/26/2026Initiated Coverage$25.89$36.00Buy
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
5/26/2026Initiated Coverage$27.84$36.00Buy
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
5/12/2026Boost Price Target$22.92$18.00Neutral
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
5/7/2026Boost Price Target$24.68$34.00Buy
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
4/7/2026Lower Price Target$14.06$31.00Buy
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
3/31/2026Lower Price Target$19.75$36.00Buy
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3/31/2026Boost Price Target$19.46$16.00Neutral
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
3/18/2026Lower Price Target$15.06$27.00Buy
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3/3/2026Boost Price Target$91.56$95.00Neutral
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
3/2/2026Boost Price Target$4.91$3.00Sell
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
3/2/2026Boost Price Target$30.13$34.00Neutral
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
1/14/2026Downgrade$17.41$10.00Sell
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
1/12/2026Upgrade$53.25$67.00Buy
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
12/11/2025Boost Price Target$32.94$38.00Buy
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
11/21/2025Boost Price Target$21.40$26.00Buy
Nuvalent, Inc. stock logo
NUVL
Nuvalent
11/18/2025Boost Price Target$105.26$135.00Buy
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
11/6/2025Reiterated Rating$27.89$40.00Buy
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
10/30/2025Boost Price Target$25.64$29.00Neutral
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
10/1/2025Reiterated Rating$6.98$7.00Neutral
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
9/30/2025Downgrade$7.17$7.00Neutral
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
9/26/2025Boost Price Target$45.58$40.00Neutral
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
9/9/2025Boost Price Target$37.15$52.00Buy
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
8/7/2025Boost Price Target$16.57$30.00Buy
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
8/6/2025Boost Price Target$52.25$82.00Buy
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
7/25/2025Initiated Coverage$15.02$18.00Neutral
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
5/14/2025Lower Price Target$4.20$18.00Buy
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
5/9/2025Lower Price Target$7.00$13.00Neutral
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
5/9/2025Lower Price Target$18.54$31.00Neutral
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
5/7/2025Lower Price Target$12.30$27.00Buy
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4/8/2025Initiated Coverage$21.52$30.00Neutral
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
3/3/2025Lower Price Target$9.15$15.00Neutral
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2/13/2025Lower Price Target$10.36$24.00Buy
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
2/11/2025Initiated Coverage$4.92$6.00Sell
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
1/17/2025Upgrade$41.47$82.00Buy